Nkarta Reports Q3 2025 Financial Results with Reduced Net Loss of $21.7 Million

Nkarta, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $21.7 million, a decrease from the $28.3 million loss recorded in the same period last year. For the nine months ending September 30, 2025, the company reported a net loss of $76.7 million, down from $82.9 million in the prior year. The reduction in losses is attributed to a decrease in operating expenses, which totaled $27.3 million for the quarter, compared to $33.8 million in Q3 2024. This decline was primarily driven by lower research and development costs, which fell to $20.2 million from $25.3 million year-over-year.

The company’s total operating expenses for the nine months ended September 30, 2025, were $91 million, down from $97.3 million in the same period of 2024. The decrease in expenses is largely due to a reduction in personnel costs following a workforce reduction in March 2025, which eliminated approximately 34% of the company's staff. General and administrative expenses also saw a slight increase, totaling $25.9 million for the nine-month period, compared to $23.7 million in the previous year, largely due to severance costs associated with the workforce reduction.

Nkarta's cash, cash equivalents, and investments stood at $316.5 million as of September 30, 2025, an increase from $273.3 million at the end of 2024. The company generated $99.2 million in cash from investing activities during the nine months, primarily from the maturity and sale of marketable securities. However, it reported a net cash outflow of $67.1 million from operating activities, reflecting ongoing investments in research and development, particularly for its lead product candidate, NKX019, which is being developed for autoimmune diseases.

Strategically, Nkarta has made significant advancements in its clinical trials, including the addition of primary membranous nephropathy as an indication for its Ntrust-1 trial. The company has also modified its lymphodepleting conditioning regimen to enhance the efficacy of NKX019. Despite these developments, Nkarta continues to face challenges, including the need for additional capital to fund ongoing operations and clinical trials. The company has indicated that it may seek further funding through equity or debt financing, as it has not yet generated revenue from product sales.

Looking ahead, Nkarta anticipates continued net losses as it invests heavily in the development of its product pipeline. The company remains focused on advancing its clinical trials and expanding its research efforts, while also managing its operational costs. Nkarta's ability to secure additional funding will be critical to its long-term success and the potential commercialization of its therapies.